Association Between Polymorphisms of ERCC1 and XPD and Clinical Response to Platinum-Based Chemotherapy in Advanced Non–Small Cell Lung Cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  American Journal of Clinical Oncology

• Publication date

  2010-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/COC.0b013e3181b9cedcPMID 20351547
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of advanced non small cell lung cancer.

  2011cited by this paper
• Multiple gene methylation of nonsmall cell lung cancers evaluated with 3‐dimensional microarray

  2008cited by this paper
• Gel immobilization of acrylamide‐modified single‐stranded DNA template for pyrosequencing

  2007cited by this paper
• Bisulfite modification of immobilized DNAs for methylation detection.

  2007cited by this paper
• Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer

  2006cited by this paper
• An improved gel‐based DNA microarray method for detecting single nucleotide mismatch

  2006cited by this paper
• Pharmacogenetics in Gastrointestinal Tumors

  2005cited by this paper
• Applications of genomics in NSCLC.

  2005cited by this paper
• High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer

  2005cited by this paper
• The role of p53 in treatment responses of lung cancer.

  2005cited by this paper
• ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer

  2005cited by this paper
• Predicting drug response and toxicity based on gene polymorphisms.

  2005cited by this paper
• The treatment of advanced non-small cell lung cancer

  2005cited by this paper
• Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.

  2005cited by this paper
• Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.

  2005cited by this paper
• Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints.

  2004cited by this paper
• A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

  2004cited by this paper
• Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.

  2004cited by this paper
• Multiple Protein-Protein Interactions by RNA Polymerase I-Associated Factor PAF49 and Role of PAF49 in rRNA Transcription

  2004cited by this paper
• Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

  2004cited by this paper
• Genetic testing for chemotherapy in non-small cell lung cancer.

  2003cited by this paper
• The world health report 2002 - reducing risks, promoting healthy life.

  2003cited by this paper
• Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

  2002cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.

  2001cited by this paper
• A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.

  2001cited by this paper
• ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

  2001cited by this paper
• Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.

  2000cited by this paper
• Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

  2000cited by this paper
• Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.

  2000cited by this paper
• Association of an ERCC1 polymorphism with adult-onset glioma.

  2000cited by this paper
• DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes.

  2000cited by this paper
• Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.

  2000cited by this paper
• ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells

  2000cited by this paper
• CAST, a Novel CD3ε-binding Protein Transducing Activation Signal for Interleukin-2 Production in T Cells*

  1999cited by this paper
• CAST, a novel CD3epsilon-binding protein transducing activation signal for interleukin-2 production in T cells.

  1999cited by this paper
• ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

  1998cited by this paper
• Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.

  1998cited by this paper
• ASE-1: a novel protein of the fibrillar centres of the nucleolus and nucleolus organizer region of mitotic chromosomes

  1997cited by this paper
• Genomic characterization of the human DNA excision repair gene ERCC-1.

  1987cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• Genetic polymorphisms of TRPA1 does affect risk of cisplatin induced nephrotoxicity in Chinese population

  2025cites this paper
• A Systematic Review of SNPs Screening for Platinum-Related Pharmacodynamics and Pharmacokinetics Genes in Non-Small Cell Lung Cancer for Precision Medicine

  2025cites this paper
• Development and validation of a LASSO prediction model for cisplatin induced nephrotoxicity: a case-control study in China

  2024cites this paper
• Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population

  2023cites this paper
• Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients

  2019cites this paper
• Relationship between clinical toxicities and ERCC1 rs3212986 and XRCC3 rs861539 polymorphisms in cervical cancer patients

  2018cites this paper
• Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.

  2018cites this paper
• Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1

  2018cites this paper
• Genetic variants in nucleotide excision repair pathway predict survival of esophageal squamous cell cancer patients receiving platinum‐based chemotherapy

  2018cites this paper
• Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

  2017cites this paper
• Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.

  2017cites this paper
• Corrupting the DNA damage response: a critical role for Rad52 in tumor cell survival

  2017cites this paper
• Association of DNA repair gene polymorphisms with the risk of radiation pneumonitis in lung cancer patients

  2017cites this paper
• Xeroderma pigmentosum complementation group D polymorphism toward lung cancer susceptibility survival and response in patients treated with platinum chemotherapy.

  2017cites this paper
• Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy

  2017cites this paper
• Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?

  2016cites this paper
• Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis

  2016cites this paper
• A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis

  2016cites this paper
• Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.

  2016cites this paper
• Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy

  2016cites this paper
• A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy

  2016cites this paper
• An investigation of the pharmacogenetic basis of toxicity to platinum chemotherapy agents

  2016influential citation
• Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells.

  2015cites this paper
• Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients

  2015cites this paper
• Frequency distribution of DNA repair genes ERCC1 and ERCC2 polymorphisms in South Indian healthy population.

  2014cites this paper
• The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis

  2014cites this paper
• Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?

  2014cites this paper
• Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies.

  2014cites this paper
• Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?

  2014influential citation
• Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.

  2013cites this paper
• Predictive Value of XPD Polymorphisms on Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

  2013cites this paper
• Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population

  2013cites this paper
• Predictive Effect of XPA and XPD Polymorphisms on Survival of Advanced NSCLC Patients Treated with Platinum-Based Chemotherapy: A Three-Dimensional (3-D), Polyacrylamide Gel-Based DNA Microarray Method

  2013influential citation
• Multi‐loci analysis reveals the importance of genetic variations in sensitivity of platinum‐based chemotherapy in non‐small‐cell lung cancer

  2013cites this paper
• Polymorphisms in XPD Gene Could Predict Clinical Outcome of Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer Patients: A Meta-Analysis of 24 Studies

  2013cites this paper
• Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.

  2013cites this paper
• Important Roles of ERCC1 in DNA Repair and Targeted Therapy

  2013cites this paper
• Platinum-Based Chemotherapy : A Three-Dimensional ( 3-D ) , Polyacrylamide Gel-Based DNA Microarray Predictive Effect of XPA and XPD Polymorphisms on Survival of Advanced NSCLC Patients Treated with

  2013influential citation
• Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.

  2012cites this paper
• RAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer

  2012cites this paper
• Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients

  2012cites this paper
• Les nouveautés dans les carcinomes broncho-pulmonaires non à petites cellules

  2012cites this paper
• Single nucleotide polymorphisms in NOS2A and NOS3 genes are not associated with treatment response of non-small cell lung cancer patients following the definitive radiochemotherapy.

  2012cites this paper
• Personalized Cancer Medicine

  2012cites this paper
• Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapy

  2012influential citation
• Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients

  2012cites this paper
• The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma.

  2012cites this paper
• Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster

  2012cites this paper
• Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.

  2011cites this paper
• No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.

  2011cites this paper
• Molecular analysis of DNA repair gene methylation and protein expression during chemical-induced rat lung carcinogenesis.

  2011cites this paper
• Genetic Variation Predicting Cisplatin Cytotoxicity Associated with Overall Survival in Lung Cancer Patients Receiving Platinum-Based Chemotherapy

  2011cites this paper
• The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity.

  2011cites this paper
• SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients.

  2011cites this paper
• Pharmacogenomics and Personalized Medicine Dovepress Ercc1 and Xrcc1 as Biomarkers for Lung and Head and Neck Cancer

  year unknowncites this paper